205. 脆弱Ｘ症候群関連疾患 Fragile X syndrome related disease Clinical trials / Disease details
臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 5) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 25
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05233579 (ClinicalTrials.gov) | June 25, 2021 | 20/10/2021 | Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS | Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS to Find Biomarkers | Fragile X Associated Tremor/Ataxia Syndrome (Fxtas) (Diagnosis) | Dietary Supplement: Sulforaphane | University of California, Davis | NULL | Recruiting | 50 Years | 85 Years | All | 15 | N/A | United States |
| 2 | NCT02603926 (ClinicalTrials.gov) | October 2015 | 5/11/2015 | Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone | Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone | Fragile X-associated Tremor/Ataxia Syndrome | Drug: Allopregnanolone | Randi J. Hagerman, MD | NULL | Completed | 50 Years | 85 Years | All | 6 | Phase 2 | United States |
| 3 | NCT02197104 (ClinicalTrials.gov) | January 2015 | 14/7/2014 | Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome | Phase 2 Study of Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome | Fragile X Tremor/Ataxia Syndrome | Drug: citocoline | Rush University Medical Center | NULL | Completed | 18 Years | 90 Years | All | 10 | Phase 2 | United States |
| 4 | NCT00584948 (ClinicalTrials.gov) | September 2007 | 22/12/2007 | Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome | Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine | Fragile X-Associated Tremor/Ataxia Syndrome;Fragile X Premutation Carriers | Drug: Memantine;Drug: Placebo | University of California, Davis | National Institute on Aging (NIA);Forest Laboratories | Completed | 30 Years | 80 Years | All | 94 | N/A | United States |
| 5 | NCT00033293 (ClinicalTrials.gov) | March 15, 2004 | 9/4/2002 | Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma | A Pilot Study Randomized Trial of Intravenous Gammaglobulin Therapy for Patients With Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated With Chemotherapy and Prednisone | Disseminated Neuroblastoma;Localized Resectable Neuroblastoma;Localized Unresectable Neuroblastoma;Regional Neuroblastoma;Stage 4S Neuroblastoma | Biological: therapeutic immune globulin;Other: clinical observation;Drug: cyclophosphamide;Drug: prednisone;Procedure: magnetic resonance imaging;Other: laboratory biomarker analysis;Drug: Corticotropin-Releasing Hormone | Children's Oncology Group | National Cancer Institute (NCI) | Active, not recruiting | N/A | 8 Years | All | 53 | Phase 3 | United States;Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland |